The ARHGEF12 Knockout HAP1 Polyclonal Cells represent a powerful loss-of-function model generated through CRISPR/Cas9-mediated gene disruption of the ARHGEF12 locus in the HAP1 human cell line. This polyclonal knockout cell population provides a genetically heterogeneous pool of cells with targeted inactivation of the ARHGEF12 gene, enabling robust functional studies without the clonal selection bottlenecks. The product is supplied as a ready-to-use polyclonal knockout cell mixture, facilitating immediate application in downstream biochemical and cell-based assays.
The HAP1 host cell line is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia (CML) cell line, of male origin. Its near-haploid karyotype makes it an exceptionally tractable system for functional genomics, where single-copy disruption of genes directly yields loss-of-function phenotypes, simplifying genetic analysis. HAP1 cells retain key signaling networks relevant to CML and serve as a valuable model for dissecting leukemia-associated pathways.
ARHGEF12, also known as LARG, functions as a RhoA-selective guanine nucleotide exchange factor. Upon activation of G??12/13-coupled receptors, including the thrombin receptor (PAR1) and LPA receptors, LARG is recruited to the plasma membrane and catalyzes GDP/GTP exchange on RhoA. Active RhoA triggers a signaling cascade through the kinases ROCK1/2 and LIMK1, which phosphorylate cofilin to promote actin polymerization, stress fiber formation, and cell migration. LARG serves as a key integrator of signals from GPCRs, Wnt receptors, and receptor tyrosine kinases such as IGF-1R, and interacts with adaptor proteins like DLG1/SAP97 and focal adhesion kinase (FAK) to coordinate cytoskeletal remodeling and SRF-dependent transcription.
In the context of the HAP1 leukemic background, ARHGEF12-mediated RhoA activation may contribute to aberrant proliferation, survival, and invasive behavior characteristic of CML and other leukemias. Disruption of ARHGEF12 in this model enables researchers to parse the specific contributions of LARG-dependent RhoA signaling to leukemic cell phenotypes, separate from other RhoA activators. This system provides a defined genetic background to investigate how GPCR-driven RhoA pathways intersect with leukemic transformation and drug resistance mechanisms.
The ARHGEF12 Knockout HAP1 Polyclonal Cells are suited for functional genomics and signaling studies. Researchers can employ Western blotting and RT-qPCR to confirm ARHGEF12 disruption and assess downstream RhoA effectors. Functional assays include RhoA activation assays (G-LISA) to directly measure RhoA activity, immunofluorescence microscopy to visualize actin stress fibers, transwell migration and wound healing assays to evaluate cell motility, and cell adhesion and proliferation assays. The polyclonal nature of the knockout population enhances robustness in high-throughput drug sensitivity screening applications. For further technical information and customized solutions, please contact Ascent Research.
